Streetbeat News

Products Services

MTEK

Maris-Tech has received a $700K order for an AI-enabled video system designed for armored vehicles. The high-end system aims to enhance driving and control capabilities, with deliveries expected in tranches from 2024 to 2027.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:43 pm

CRVS

Corvus Pharmaceuticals has received FDA Fast Track designation for its drug Soquelitinib, aimed at treating relapsed or refractory peripheral T-cell lymphoma (PTCL). The company plans to begin initial enrollment for a Phase 3 clinical trial in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:41 pm

MBOT

Microbot Medical Inc. (NASDAQ:MBOT) has entered into an agreement with Emory University to evaluate the potential for integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for endovascular procedures.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:41 pm

ENTX

Entera Bio Ltd. (NASDAQ:ENTX) will present new data on its investigational agent EB613, a once-daily oral PTH(1-34) mini tablet therapy for post-menopausal women with high-risk osteoporosis, at the ASBMR 2024 Annual Meeting. The presentation will include comparative pharmacological data between EB613 and Forteo®.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:40 pm

AAPL

NVDA

SOXX

TDIV

TSM

Taiwan Semiconductor Manufacturing Co (NYSE:TSM) has seen a surge in retail investor support in Taiwan, driven by financial interests and national security concerns. Despite foreign investors' withdrawal, retail ownership has increased significantly, reflecting the belief that TSMC's success is crucial for Taiwan's defense. TSMC's stock has surged 69% in the last 12 months, and investors can gain exposure through ETFs like iShares Semiconductor ETF (NASDAQ:SOXX) and First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:TDIV).

Portfolio Pulse from Anusuya Lahiri

August 01, 2024 | 12:40 pm

PRFX

PainReform Ltd. (NASDAQ:PRFX) has announced a significant advancement in the development of its lead asset, PRF-110. The company has developed a new manufacturing process that allows PRF-110 to remain stable for 18 months at room temperature, a major milestone for the clinical-stage specialty pharmaceutical company.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:39 pm

MBRX

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced plans for a pivotal, adaptive Phase 3 clinical trial (MIRACLE trial) for the possible accelerated approval of Annamycin in combination with Cytarabine for treating relapsed or refractory AML. The decision follows a positive discussion with the FDA.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:36 pm

COIN

Vice President Kamala Harris is pivoting towards the cryptocurrency sector to gain support from Silicon Valley's tech community, as her chances of winning the 2024 presidential race stand at 43% according to Polymarket. Her campaign has reached out to Bitcoin advocate Mark Cuban and is considering meetings with industry giants like Ripple, Coinbase, and Circle.

Portfolio Pulse from Murtuza Merchant

August 01, 2024 | 12:35 pm

SLP

Simulations Plus has released an updated version of its QST software, DILIsym Version X, which is designed to investigate and predict drug-induced liver injury.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:35 pm

GH

Guardant Health has announced FDA approval and Medicare coverage for its Shield blood test, which is now commercially available as the first FDA-approved blood test for primary colorectal cancer screening.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:33 pm